A Diagnostics-Driven Antifungal Stewardship Programme

Antimicrobial stewardship (AMS) aims to preserve the future effectiveness of antimicrobial agents and to reduce unintended adverse patient outcomes related to overuse.

Promoting selection of the optimal antimicrobial regimen, duration and route of administration are key in this endeavour.

There are two fundamental tools in AMS: guidelines for empirical therapy; and reliable diagnostic tests that can guide initiation and discontinuation of antimicrobial therapy. Antifungal stewardship (AFS) shares the aims and approaches of AMS but has its own specific features and challenges, which include limited availability of diagnostic testing, long laboratory turn-around times, the lack of AFS expertise outside specialist centres and a paucity of evidence identifying effective AFS interventions outside specific patient cohorts. Due to these challenges, there is a need for different leadership and communication models if AFS is to be effectively practised.

The focus of most AFS programmes has been on the management of invasive candidosis, the most common severe nosocomial fungal infection.5 However, to date, most attention has been paid to reducing the use of expensive antifungal agents rather than the impact of AFS on patient outcomes or antifungal resistance.

Candida species are an increasingly prevalent cause of bloodstream infections (BSIs) in the ICU.

Although candidaemia has a high attributable mortality, there is significant variation between centres and patient groups.

Early and appropriate initiation of antifungal therapy has been reported to improve outcomes.

Blood cultures remain the mainstay of diagnosis but their sensitivity is poor due to the low intensity of fungaemia.

This is a major challenge also for molecular methods. Biomarker tests such as serumb-1–3-Dglucan (BDG) are available but their specificity is low.

Therefore, clinicians often rely on their clinical experience and judgement. This has led to overuse of empirical and prophylactic antifungal therapy, in particular echinocandins, inmany ICUs.

The AFS programme at Wythenshawe Hospital has been developed over the past 8 years. The key targets of the programme are to improve patient outcomes by:

(i) updating and clarifying antifungal guidelines;
(ii) involving and educating champions;
(iii) improving access to timely diagnostic testing; and
(iv) reducing unnecessary use of antifungal therapy.

A local guideline for suspected or proven invasive candidosis (Figure 1) was developed based upon the ESCMID guideline for diagnosis and management of invasive candidosis in nonneutropenic adult patients.

Due to its very high negative predictive value in a low prevalence setting such as ours, serum BDG testing was introduced as a rule-out test to guide the discontinuation of therapy in the absence of other microbiological evidence of invasive candidosis.

The launch of the guideline in January 2014 was followed up by an online clinical educational quiz for prescribers, circulation of guideline posters, and the active presence of the Infectious Diseases (ID) teamin the ICUs. An intensive-care physician was recruited by the AFS teamas an AFS champion.

The aim of this project was to evaluate the compliance of the ICUs with the current local guideline. Additionally, we aimed to evaluate the impact of the AFS programme on the use of antifungal therapy, and onmortality due to invasive candidosis.

Methods
There are two separate ICUs in Wythenshawe Hospital staffed by separate intensive-care teams:

(i) a cardiothoracic and heart-lung transplant ICU; and
(ii) amixedmedical and surgical (including burns) ICU; these two ICUs have a total of 71 beds. The compliance of the intensivecare teams with the current local invasive candidosis guideline was audited over a 4month audit period (April–July) in 2014 and

ANTIFUNGAL STEWARDSHIP IN THE ICU

UHSM INVASIVE CANDIDOSIS IN CRITICAL CARE ALGORITHM

1. Persisting clinical signs of infection?
Fever or other ongoing SIRS response especially if despite broad-spectrum antibacterials (±fluconazole prophylaxis)

NO
Consider other causes & reassess

2. Host risk factors present?
Steroids/immunosuppressives, Candida in clinical samples, TPN, unresolved abdominal sepsis, central venous lines, neutropaenia, haematological malignancy, renal support, burns

NO
Consider other causes & reassess

YES ≥ 2

SUSPECTED INVASIVE CANDIDOSIS?
(Sometimes referred to as "possible" or "probable" in other guidelines)

PROVEN INVASIVE CANDIDOSIS?
i.e isolation of Candida from a normally sterile site (Blood Cultures, deep tissue specimen line tip)

1. Send samples to microbiology
- 2 sets of blood cultures (with FAN bottle if on antimicrobials)
- Serum sample for beta-D-1,3-glucan test (Fungitell)
- Line tips Sometimes when removed
- Infected tissue / pus if present

2. Commence antifungal therapy
1st line: iv echinocandin (micafungin 100 mg OD (> 40kg wt) or 2 mg/kg rounded up to nearest 50mg OD (<40 kg)
2nd line and if echinocandin contraindicated (allergy, history of echinocandin therapy): iv amphotericin B (AmBisome 3mg/kg od)
- Consult the Infectious Diseases team

3. Review microbiology results at 48-96 hours

NEGATIVE   POSITIVE

Stop antifungals

Reconsider diagnosis & reassess

If indicated repeat investigation twice weekly

Note: Negative beta-D-1,3-glucan test rules out candidaemia if sterile site cultures are also negative

Treatment of uncomplicated candidaemia is normally for **two weeks after the last positive blood clulture**

Repeat blood cultures @48-72 hours to assess clearance

Switch to oral fluconazole can be considered after 10 days if the causative Candida is susceptible to it.

Change lines & ensure to deep focus of infection

Examine eyes to exclude endophthalmitis (at least one dilated retinal examination) and cardiac vales for endocarditis (cardiac echo)

Note: Positive beta-D1,3-glucan test alone is not an indication for continued treatment.

REFERENCES:
Cornely OA et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect. 2012 Suppl 7:19-37.
Eggimann P, Marchetti O. Is (1→3)-(3-D-glucan the missing link from bedside assessment to pre-emptive therapy of invasive candidiasis? Crit Care. 2011:15(6):1017

v 1. 02 July 2013 R Richardson

reaudited over the same period in 2016.

All patients who were prescribed micafungin during the audit periods were identified from pharmacy databases. Patients treated for indications other than suspected or proven invasive candidosis, or those not admitted to an ICU, were excluded from analysis. All prescriptions were reviewed by the audit team against the local guideline (Figure 1). During the 2014 audit period the AFS team actively followed up patients who were prescribed micafungin, and guided the use and interpretation of diagnostic testing.

In 2016, therewas no additional involvement beyond routine clinical practice.

As per the local guideline (Figure 1), patients with Candida spp. Isolated fromblood cultures were classified as 'proven invasive candidosis'. Patients with persistent clinical symptoms, host risk factors for candidosis and with

other diagnostic evidence of invasive candidosis (e.g. positive serumBDG or Candida spp. isolated from line tip cultures) were classified as 'probable invasive candidosis'. The use of antifungal therapy was defined as appropriate in all patients with proven or probable invasive candidosis. Patients with persistent clinical symptoms and host risk factors for candidosis but with negative blood cultures were classified as 'suspected invasive candidosis'.

Initiation of antifungal therapy was deemed appropriate in patients with persistent clinical

Symptoms and host risk factors for candidosis but no diagnostic evidence of invasive candidosis (e.g. negative blood culture for Candida or negative BDG). In contrast, antifungal therapy was deemed inappropriate in patients with 'suspected invasive candidosis' but with no clinical symptoms and/or host risk factors for candidosis.

Hospital micafungin consumption data were analysed for a 3 year period (April 2014–March 2017). The data were obtained from the AFS team database. Appropriateness of antifungal treatment, compliance with the guideline, all-cause mortality during the 4month audit periods and micafungin consumption were used as outcome measures.

The incidence of invasive candidosis at Wythenshawe Hospital was audited for a 12 year period (2005–16). Cases of Candida spp. BSIs were identified from laboratory databases and the incidence calculated per 100000 bed-days.

Statistical analysis
Comparison of the proportions of patients with 'proven or probable invasive candidosis', 'appropriately suspected but candidosis excluded' or 'inappropriately suspected' in 2014 and 2016 was made using a Pearson v2 test and two-proportion Z-tests in SPSS version 22 (IBM Corp., Armonk, NY, USA).

Analysis of changes in the incidence of invasive candidosis was made by linear regression. Statistical significance was set at P,0.05.

Ethics
This study was a retrospective service evaluation and ethical approval was not required, as Per UK Health Research Authority guidelines.

Results
2014 audit period
During the 4month period in 2014, 39 patients admitted to ICU were treated for suspected or proven invasive candidosis (Figure 2a). Of these, 6 (15%) had Candida spp. Isolated from blood cultures, with 3 patients receiving extracorporeal membrane oxygenation (ECMO). All patients with proven invasive candidosis were treated according to the local guideline.

When assessed by the AFS team, the initiation of micafungin treatment was deemed appropriate in 15/33 (45%) of the suspected invasive candidosis cases; in 3/15 (20%) patients micafungin was continued for at least 2weeks (Figure 2a).

For the remaining 12/15 (80%) patients treatment was discontinued within 1week following advice from the AFS team, based upon negative blood culture or BDG result. Overall for those patients where treatment was deemed appropriate, 14/15 (93%) had blood cultures taken and 6/13 (46%) had BDG tests performed. One patient was prescribed a higher dose (150mg) of micafungin in the absence of clinical suspicion of aspergillosis or oesophageal candidosis.

In 18/33 (55%) cases of suspected invasive candidosis the initiation of treatment was deemed inappropriate. In 15/18 (83%) the indication recorded for the initiation of micafungin therapy

was Candida spp. isolated from a single non-sterile site sample such as sputumor urine in the absence of clear risk factors for invasive candidosis.

In 3/18 cases there was no clear indication of fungal infection. Micafungin treatment was discontinued within 1week on the advice of the AFS in 13/18 (72%) cases where it was deemed inappropriate.

Overall, only 10/33 (30%) patients with suspected invasive candidosis had serum BDG requested and only one was taken at the time of initiation of micafungin therapy. Of all samples, 9/10 (90%) were negative.

The correctly timed sample was negative but was not used to guide the stopping of therapy as the patient died soon after treatment was initiated.

None of the patients with proven invasive candidosis died within 30 days of micafungin initiation. Eight patients with suspected invasive candidosis died within 30 days of the initiation of treatment.

These patients suffered from:
multi-organ failure whilst on ECMO (n"1), pulmonary haemorrhage (n"1), postsurgical complications (n"2), pneumonia (n"3) and interstitial lung disease (n"1). None of these patients had BDG testing performed on initiation of micafungin therapy. One patient who was

on ECMO had Candida albicans DNA detected by PCR in blood and died 8 days after initiation of micafungin; however, this patient was also bacteraemic with Klebsiella and Escherichia species.

2016 audit period

Twenty-nine patients admitted to ICU were treated for suspected or proven invasive candidosis (Figure 2b). Of these, 4/29 (14%) had Candida spp. Isolated from blood cultures. All patients (n"4) with proven invasive candidosis were treated according to the local guideline and all had positive serumBDG test results.

When assessed by the AFS team, the initiation of micafungin treatment was deemed appropriate in 23/25 (92%) patients with suspected invasive candidosis (Figure 2b). The treatment was discontinued within a week for 9/23 (39%) patients following advice from the AFS team, based on negative blood culture and/or BDG results. For 14/23 (61%) patients the treatment was continued for 2weeks based on positive BDG or other clinical factors. Overall, of those patients for whom the initiation of treatment was deemed appropriate, 21/23 (91%)

had blood cultures done, and 21/23 (91%) had BDG done; 8/21 (38%) BDG results were negative, and in 5 cases the negative result was used to guide discontinuation of therapy. One patient was prescribed a higher dose (150mg) of micafungin in the absence of clinical suspicion of aspergillosis or oesophageal candidosis.

In 2/25 (8%) cases of suspected invasive candidosis the treatment was deemed inappropriate by the AFS team. In one case the indication recorded for the initiation of micafungin therapy was Candida spp. isolated from sputum in the absence of clear risk factors for invasive candidosis. In the other case there was no clear indication of fungal infection. Treatment was inappropriately continued for both patients. One patient had a blood culture performed but no BDG testing, and the other had neither blood culture nor BDG testing.

No patient with proven invasive candidosis died within 30 days of micafungin commencement. Eight patients with suspected invasive candidosis died within 30 days of micafungin initiation. These patients suffered from: multiorgan failure whilst on ECMO (n"2) or left ventricular assist device (LVAD) (n"1), post-surgical complications (n"3), pneumonia (n"1) and bacterial sepsis (n"1).

Comparison of 2014 and 2016

Between 2014 and 2016, there were significant changes in the numbers of patients categorized as 'proven or probable invasive candidosis', 'appropriately suspected but candidosis excluded' and 'inappropriately suspected' (P"0.01). The number of patients with 'proven or probable invasive candidosis' significantly increased from 9/39 (23%) in 2014 to 18/29 (62%) in 2016. Over the same period the number of patients 'inappropriately suspected' significantly reduced from18/39 (46%) to 2/29 (7%).

Micafungin and laboratory expenditure

The monthly micafungin expenditure at the Wythenshawe Hospital decreased from £81000 (e90000) per month to £40000 (e45000) (#49%) during the 24month follow-up (Figure 3). There was no change in the vial price of micafungin or in the consumption of other antifungal agents over the same period.

The BDG measurements were provided by the Mycology Reference Laboratory (MRCM) located at the Wythenshawe Hospital site. The mean monthly consumable costs for BDG tests (Fungitell, Associates of Cape Cod, MA, USA) in 2016 were £3739, which allows up to 21 tests done twice weekly. The cost of laboratory technician time (6h per week) to do the tests was some £390 per month. Therefore, the total cost of BDG testing at Wythenshawe Hospital was £4129 per month.

Invasive candidosis incidence

The total number of patients reported with Candida spp. In blood cultures and the incidence of Candida BSIs per 100000 bed-days at Wythenshawe Hospital between 2005 and 2016 are summarized in Figure 4. The incidence of culture positive invasive candidosis at Wythenshawe Hospital decreased significantly from 7.7/ 100000 bed-days in 2007 to 5.7/100000 bed-days in 2016 (R2"0.44, P"0.037; Figure 4a).

The number of cases with Candida spp. isolated from the blood stream on ICUs has remained stable (Figure 4b). In most years, C. albicans was the most common finding, followed by Candida glabrata and Candida parapsilosis.

There has been no marked change in the species distribution over the years.

Discussion
Successful AFS programmes build on implementation of guidelines for prompt administration of empirical antifungal therapy coupled with diagnostic tests that can guide safe discontinuation of therapy.

The aim of our programme was not to restrict the initiation of antifungal therapy in patients at risk of invasive Candida infection, as timely administration of empirical antifungal agents to patients with invasive candidosis is associated with reduced mortality.[18,19]

During the data collection periods in 2014 and 2016, the overall crude mortality in patients with proven or probable invasive candidosis was 19% (5/27). This compares favourably with the overall crude mortality due to invasive candidosis of 45% (a reduction of 58%), reported by our centre for the period of 2003–07,[27] and.35%by others.[16,28]

The knowledge that early initiation of antifungal therapy improves outcomes, and the introduction of less toxic antifungal agents, such as the echinocandins, puts pressure on clinical teams to treat patients with early empirical therapy. Full diagnostic workup including investigations for alternative causative organisms and use of fungal biomarkers such as serum BDG to guide discontinuation of antifungal therapy is fundamental for avoiding overuse of antifungal drugs. Our AFS strategy led to a 90%reduction in inappropriately initiated courses between 2014 and 2016.

Reassuringly, the number of patients in whom invasive candidosis was appropriately suspected but excluded did not increase between 2014 and 2016. This demonstrates that the guideline recommending early initiation of antifungal therapy was not driving an increase in unnecessary empirical antifungal use. In contrast, the overall antifungal consumption approximately halved during the 2 year study period (Figure 3). This is in keeping with the reduction in the number of inappropriately initiated empirical antifungal courses during the same time period. A marked temporal variability is demonstrated in the use of antifungal agents.

The number of patients with proven or probable invasive candidosis doubled from 9 in 2014 to 18 in 2016. This increase is largely due to an increase in the number of patients with probable invasive candidosis as a result of increased use of the BDG test. However, the number of patients with Candida species isolated from blood culture in all of 2016 increased compared with 2015 and 2014 (Figure 4a). Figure 4 also demonstrates the marked natural fluctuation in the number of cases each year, which is likely to contribute to the spike in 2016. This does not, however, detract from the general trend towards a reduction in cases with Candida reported from blood culture.

Intravenous antifungal agents are commonly prescribed empirically for patients at risk of invasive fungal infections. These high-risk patients are typically cared for by clinical specialties familiar with invasive fungal infections such as intensive-care medicine, haematology and transplantation. However, there is a growing body of evidence that the involvement of infection specialists will improve outcomes in patients within these cohorts diagnosed with complex infection.29 Implementing an AFS programme is challenging and requires credibility and good interpersonal skills to influence clinical practice. Our approach of recruiting an intensive-care champion facilitated an excellent working relationship between the ID and intensive-care teams, to which we attribute our success in influencing practice.

The close working relationship between the AFS champion and ID team, fostered confidence in the clinical assessment of patients with suspected invasive candidosis, and increased the use of diagnostic tests, thus improving compliance with the local guideline. This ultimately led to a reduction in the input required from the AFS team and the resources needed for stewardship rounds.

Antifungal agents remain expensive and decreasing inappropriate use will affect the healthcare costs of ICU patients.

The monthly expenditure on BDG testing is equivalent to 20 doses of micafungin. Any additional doses that were not administered contributed to the increased savings. In this, minimizing laboratory turnaround times is key to success. By involving AFS champions, this can be achieved with minimal additional clinical staff costs. Due to the design of the BDG test kit the cost per test is lower the more tests are done at a time, which highlights the benefits of laboratory centralization. It is important to acknowledge that the incidence of candidaemia affects the negative predictive value of the BDG test, which is high only in low incidence settings.

There are some limitations to this study. Firstly, the sample size is limited due to the low incidence of invasive candidosis.

As the focus of this study was to audit the adaptation of the new ICU candidaemia guideline, only patients in ICUs were included.

However, the majority of candidaemias occur in the ICU, and during the audit periods there were no patients with invasive candidosis on non-ICU wards. Secondly, this was a retrospective study and the data collection depended on documentation in patient records. However, the key variables analysed were available for all patients. During the audit periods there were no significant changes in the provision of clinical services at the University Hospital of South Manchester or overall mortality on ICUs.

Thus it is likely that the reduction in mortality due to invasive candidosis was due to the implementation of the AFS programme. The impact of seasonal variation in candidaemia was minimized by including the same months in both audit periods.

To further analyse the effectiveness of AFS, a prospective multicentre study using a stepped-wedge, cluster randomized trial design would be ideal. In conclusion, our real-world experience demonstrates that a clear and concise clinical guideline utilizing an informative biomarker and implemented with the help an AFS champion can be safe and effective at reducing inappropriate initiation of antifungal agents as well as improving patient outcomes. The cost of instituting the AFS programme was more than covered by the savings associated with reduced antifungal consumption.

Funding

References

1. Nathwani D, Sneddon J, Patton A et al. Antimicrobial stewardship in Scotland: impact of a national programme. Antimicrob Resist Infect Control 2012; 1: 7.

2. NICE. Antimicrobial Stewardship Quality Standard QS121. 2016. https:// www.nice.org.uk/guidance/qs121.

3. Denning DW, Perlin DS,Muldoon EG et al. Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities. Emerg Infect Dis 2017; 23: 177–83.

4. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis 2017; 17: e383–92.

5. PfallerMA, CastanheiraM. Nosocomial candidiasis: antifungalstewardship and the importance of rapid diagnosis. MedMycol 2016; 54: 1–22.

6. Valerio M, Rodriguez-Gonzalez CG, Munoz P et al. Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob Chemother 2014; 69: 1993–9.

7. Valerio M, Munoz P, Rodriguez CG et al. Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clin Microbiol Infect 2015; 21: 491–9.

8. Cook PP, Gooch M. Long-termeffects of an antimicrobial stewardship programme at a tertiary-care teaching hospital. Int J Antimicrob Agents 2015; 45: 262–7.

9. Munoz P, Valerio M, Vena A et al. Antifungal stewardship in daily practice and health economic implications. Mycoses 2015; 58 Suppl 2: 14–25.

10. Micallef C, Aliyu SH, Santos R et al. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England.JAntimicrobChemother 2015; 70: 1908–11.

11. Shahin J, Allen EJ, Patel K et al. Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdomcritical care units. BMC Infect Dis 2016; 16: 480.

12. Sasso M, Roger C, Sasso Met al. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: a 10-year study. Mycoses 2017; 60: 770–80.

13. BaldesiO, Bailly S, Ruckly S et al. ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004-2013—a study from the REA-RAISIN network. J Infect 2017; 75: 59–67.

14. O'Leary RA, Einav S, Leone M et al. Management of invasive candidiasis and candidaemia in critically ill adults: expert opinion of the European Society of Anaesthesia Intensive Care Scientific Subcommittee. J Hosp Infect 2018; 98: 382–90.

15. Bougnoux ME, Kac G, Aegerter P et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence,molecular diversity, management and outcome. Intensive Care Med 2008; 34: 292–9.

16. Colombo AL, Guimaraes T, Sukienik T et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. IntensiveCareMed2014; 40: 1489–98.

17. Chakrabarti A, Sood P, Rudramurthy SM et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015; 41: 285–95.

18. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640–5.

19. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study. Clin Infect Dis 2006; 43: 25–31.

20. Metwally L, Fairley DJ, Coyle PV et al. Improving molecular detection of Candida DNA inwhole blood: comparison of seven fungal DNA extraction protocols using real-time PCR. JMedMicrobiol 2008; 57: 296–303.

21. Clancy CJ, NguyenMH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56: 1284–92.

22. Ferreira D, Grenouillet F, Blasco G et al. Outcomes associatedwith routine systemic antifungal therapy in critically ill patients with Candida colonization. Intensive CareMed 2015; 41: 1077–88.

23. Rouze A, Loridant S, Poissy J et al. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. IntensiveCareMed2017; 43: 1668–77.

24. Cornely OA, BassettiM, Calandra T et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: nonneutropenic adult patients. ClinMicrobiol Infect 2012; 18 Suppl 7: 19–37.

25. Pickering JW, Sant HW, Bowles CA et al. Evaluationofa(1!3)-b- D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957–62.

26. NucciM, Noue´r SA, Esteves P et al. Discontinuation ofempirical antifungal therapy in ICU patients using 1,3-b-D-glucan. J Antimicrob Chemother 2016; 71: 2628–33.

27. Hassan I, Powell G, SidhuMet al. Excessmortality, length of stay and cost attributable to candidaemia. J Infect 2009; 59: 360–5. 28. Bassetti M, Righi E, Ansaldi F et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive CareMed 2015; 41: 1601–10.

29. Farmakiotis D, Kyvernitakis A, Tarrand JJ et al. Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. ClinMicrobiol Infect 2015; 21: 79–86.